RecruitingPreeclampsia
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Eligible age
18–50 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Individuals with \< 34 0/7 weeks of gestation.
- ✓ Individuals with severe preeclampsia or HELLP features.
You may not qualify if…
- ✕ Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
- ✕ Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.
Where it's recruiting
Minnesota
Rochester
Source: ClinicalTrials.gov · NCT06333652 · last updated 2026-04-28